Anita Wolfer

Bern, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001-2020): A Meta-Analysis of Pivotal Randomised Controlled Trials.

Efficacy and Safety Evidence Supporting Cancer Drug Approvals in Switzerland (2001-2020): A Meta-Analysis of Pivotal Randomised Controlled Trials.

Journal: The Lancet regional health. Europe

Published: January 23, 2026

Navigating the complexity: reflections on the development of perioperative cancer treatments.

Navigating the complexity: reflections on the development of perioperative cancer treatments.

Journal: The Lancet. Oncology

Published: April 06, 2025

Oncology. Antibody-drug conjugates : a challenging innovation

Oncology. Antibody-drug conjugates : a challenging innovation

Journal: Revue medicale suisse

Published: January 23, 2025

Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study.

Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 14, 2024

Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.

Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.

Journal: The Lancet. Oncology

Published: December 22, 2023

Decision-Making at Swissmedic, the Swiss Regulatory Agency, with a Focus on (Neo)adjuvant Cancer Treatments.

Decision-Making at Swissmedic, the Swiss Regulatory Agency, with a Focus on (Neo)adjuvant Cancer Treatments.

Journal: Oncology

Published: December 05, 2023

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.

Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 21, 2023

A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.

A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.

Journal: Clinical and translational science

Published: March 31, 2023

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.

Journal: Cancer biology & therapy

Published: March 27, 2023

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

Journal: Gynecologic oncology

Published: May 15, 2019

Actualities in endometrial carcinoma

Actualities in endometrial carcinoma

Journal: Revue medicale suisse

Published: October 31, 2018

High grade serous ovarian cancer 2018 : advances and controversies

High grade serous ovarian cancer 2018 : advances and controversies

Journal: Revue medicale suisse

Published: May 17, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026